July 2025 – Page 11

LEO Pharma Acquires Exclusive Global Rights for Boehringer Ingelheim’s Psoriasis Drug Spevigo in €90 Million Deal

1 month ago talkbio0Tagged Boehringer Ingelheim, Drug licensing, Generalized pustular psoriasis, IL1RAP protein, human, Immunology, News [Publication Type], Partnership, Pharma, Psoriasis, spesolimab, Spevigo

LEO Pharma; Boehringer Ingelheim; Spevigo; spesolimab; psoriasis; GPP; drug licensing; immunology; IL-36 receptor; partnership; biotech news

Viome and Scripps Initiate AI-Powered At-Home RNA Test for Early Colon Cancer Risk Detection

1 month ago talkbio0Tagged AI-powered diagnostics, at-home colon cancer, Cancer Detection, Clinical Research, Colonic Polyps, Microbiome, RNA test, Screening for cancer, Scripps Research, Viome

Viome; Scripps Research; AI-powered diagnostics; RNA test; at-home colon cancer screening; colon polyps; clinical study; microbiome; early cancer detection

Takeda’s Oveporexton Succeeds in Two Phase III Trials, Paving Way for Narcolepsy Drug Filings

2 months ago talkbio0Tagged Clinical Trials, File (record), Narcolepsy, Narcolepsy type 1, orexin agonist, oveporexton, Phase 3 Clinical Trials, Takeda, United States Food and Drug Administration

Takeda; Oveporexton; narcolepsy; Phase III trials; orexin agonist; FDA filing; Narcolepsy Type 1; clinical trial results

WHO to Develop Guidelines for Gilead’s Twice-Yearly HIV PrEP Injection (Lenacapavir)

2 months ago talkbio0Tagged Approved, Gilead, Guidelines, HIV Prevention, Lenacapavir, PREP gene, twice-yearly injection, United States Food and Drug Administration, World Health Organization

WHO; Gilead; Lenacapavir; twice-yearly injection; PrEP; HIV prevention; guidelines; FDA approval

GSK’s ViiV Expands Licensing Deal to Increase Access to Long-Acting Injectable HIV Treatment

2 months ago talkbio0Tagged cabotegravir, Environmental pool, generic manufacturing, Global Health, HIV, licensing agreement, SmithKline Beecham, ViiV Healthcare

GSK; ViiV Healthcare; long-acting HIV treatment; cabotegravir; licensing agreement; Medicines Patent Pool; generic manufacturing; HIV; global health

FDA Declines Approval of Ultragenyx’s Sanfilippo Gene Therapy Due to Manufacturing Issues

2 months ago talkbio0Tagged Approved, gene therapy, manufacturing issues, Mucopolysaccharidosis Type IIIA, Regulatory Setback, Response Letter, Ultragenyx, United States Food and Drug Administration, UX111

FDA; Ultragenyx; Sanfilippo syndrome type A; gene therapy; manufacturing issues; UX111; regulatory setback; complete response letter; approval delay

AstraZeneca’s Baxdrostat Achieves Pivotal Phase 3 Success for Hypertension, Validating $1.3B CinCor Acquisition

2 months ago talkbio0Tagged Acquisition, AstraZeneca, baxdrostat, CinCor Pharma, Clinical Trials, Hypertensive disease, treatment-resistant hypertension, Uncontrolled

AstraZeneca; baxdrostat; CinCor Pharma; hypertension; high blood pressure; phase 3 trial; aldosterone synthase inhibitor; $1.3 billion acquisition; clinical trial win; uncontrolled hypertension; treatment-resistant hypertension